These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 23748114)

  • 1. Efficacy, safety, and tolerability of fulranumab, an anti-nerve growth factor antibody, in the treatment of patients with moderate to severe osteoarthritis pain.
    Sanga P; Katz N; Polverejan E; Wang S; Kelly KM; Haeussler J; Thipphawong J
    Pain; 2013 Oct; 154(10):1910-1919. PubMed ID: 23748114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy, Safety, and Tolerability of Fulranumab as an Adjunctive Therapy in Patients With Inadequately Controlled, Moderate-to-Severe Chronic Low Back Pain: A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Dose-loading Phase II Study.
    Sanga P; Polverejan E; Wang S; Kelly KM; Thipphawong J
    Clin Ther; 2016 Jun; 38(6):1435-1450. PubMed ID: 27101815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of fulranumab as monotherapy in patients with moderate to severe, chronic knee pain of primary osteoarthritis: a randomised, placebo- and active-controlled trial.
    Mayorga AJ; Wang S; Kelly KM; Thipphawong J
    Int J Clin Pract; 2016 Jun; 70(6):493-505. PubMed ID: 27238963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Safety and Efficacy of Fulranumab in Patients With Moderate-to-Severe Osteoarthritis Pain: A Phase II Randomized, Double-Blind, Placebo-Controlled Extension Study.
    Sanga P; Katz N; Polverejan E; Wang S; Kelly KM; Haeussler J; Thipphawong J
    Arthritis Rheumatol; 2017 Apr; 69(4):763-773. PubMed ID: 27748055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of fulranumab in osteoarthritis of the hip and knee: results from four early terminated phase III randomized studies.
    Kelly KM; Sanga P; Zaki N; Wang S; Haeussler J; Louie J; Thipphawong J
    Curr Med Res Opin; 2019 Dec; 35(12):2117-2127. PubMed ID: 31387410
    [No Abstract]   [Full Text] [Related]  

  • 6. Fulranumab in Patients With Pain Associated With Postherpetic Neuralgia and Postraumatic Neuropathy: Efficacy, Safety, and Tolerability Results From a Randomized, Double-blind, Placebo-controlled, Phase-2 Study.
    Wang H; Romano G; Fedgchin M; Russell L; Sanga P; Kelly KM; Frustaci ME; Thipphawong J
    Clin J Pain; 2017 Feb; 33(2):99-108. PubMed ID: 27153360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fulranumab in patients with interstitial cystitis/bladder pain syndrome: observations from a randomized, double-blind, placebo-controlled study.
    Wang H; Russell LJ; Kelly KM; Wang S; Thipphawong J
    BMC Urol; 2017 Jan; 17(1):2. PubMed ID: 28056917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fulranumab as Adjunctive Therapy for Cancer-Related Pain: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study.
    Slatkin N; Zaki N; Wang S; Louie J; Sanga P; Kelly KM; Thipphawong J
    J Pain; 2019 Apr; 20(4):440-452. PubMed ID: 30368018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fulranumab for treatment of diabetic peripheral neuropathic pain: A randomized controlled trial.
    Wang H; Romano G; Frustaci ME; Bohidar N; Ma H; Sanga P; Ness S; Russell LJ; Fedgchin M; Kelly KM; Thipphawong J
    Neurology; 2014 Aug; 83(7):628-37. PubMed ID: 25008392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fasinumab (REGN475), an antibody against nerve growth factor for the treatment of pain: results from a double-blind, placebo-controlled exploratory study in osteoarthritis of the knee.
    Tiseo PJ; Kivitz AJ; Ervin JE; Ren H; Mellis SJ
    Pain; 2014 Jul; 155(7):1245-1252. PubMed ID: 24686255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee.
    Kivitz A; Ma C; Ahdieh H; Galer BS
    Clin Ther; 2006 Mar; 28(3):352-64. PubMed ID: 16750450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Tanezumab on Joint Pain, Physical Function, and Patient Global Assessment of Osteoarthritis Among Patients With Osteoarthritis of the Hip or Knee: A Randomized Clinical Trial.
    Schnitzer TJ; Easton R; Pang S; Levinson DJ; Pixton G; Viktrup L; Davignon I; Brown MT; West CR; Verburg KM
    JAMA; 2019 Jul; 322(1):37-48. PubMed ID: 31265100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial.
    Balanescu AR; Feist E; Wolfram G; Davignon I; Smith MD; Brown MT; West CR
    Ann Rheum Dis; 2014 Sep; 73(9):1665-72. PubMed ID: 23852695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Efficacy, Tolerability, and Joint Safety of Fasinumab in Osteoarthritis Pain: A Phase IIb/III Double-Blind, Placebo-Controlled, Randomized Clinical Trial.
    Dakin P; DiMartino SJ; Gao H; Maloney J; Kivitz AJ; Schnitzer TJ; Stahl N; Yancopoulos GD; Geba GP
    Arthritis Rheumatol; 2019 Nov; 71(11):1824-1834. PubMed ID: 31207169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tanezumab for the treatment of pain from osteoarthritis of the knee.
    Lane NE; Schnitzer TJ; Birbara CA; Mokhtarani M; Shelton DL; Smith MD; Brown MT
    N Engl J Med; 2010 Oct; 363(16):1521-31. PubMed ID: 20942668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase III placebo- and oxycodone-controlled study of tanezumab in adults with osteoarthritis pain of the hip or knee.
    Spierings ELH; Fidelholtz J; Wolfram G; Smith MD; Brown MT; West CR
    Pain; 2013 Sep; 154(9):1603-1612. PubMed ID: 23707270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, tolerability, pharmacokinetics, and efficacy of AMG 403, a human anti-nerve growth factor monoclonal antibody, in two phase I studies with healthy volunteers and knee osteoarthritis subjects.
    Gow JM; Tsuji WH; Williams GJ; Mytych D; Sciberras D; Searle SL; Mant T; Gibbs JP
    Arthritis Res Ther; 2015 Oct; 17():282. PubMed ID: 26449617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CGRP blockade by galcanezumab was not associated with reductions in signs and symptoms of knee osteoarthritis in a randomized clinical trial.
    Jin Y; Smith C; Monteith D; Brown R; Camporeale A; McNearney TA; Deeg MA; Raddad E; Xiao N; de la Peña A; Kivitz AJ; Schnitzer TJ
    Osteoarthritis Cartilage; 2018 Dec; 26(12):1609-1618. PubMed ID: 30240937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preliminary assessment of the safety and efficacy of tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee: a randomized, double-blind, dose-escalation, placebo-controlled study.
    Nagashima H; Suzuki M; Araki S; Yamabe T; Muto C;
    Osteoarthritis Cartilage; 2011 Dec; 19(12):1405-12. PubMed ID: 22004765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post hoc analysis of a randomized, double-blind, placebo-controlled efficacy and tolerability study of tramadol extended release for the treatment of osteoarthritis pain in geriatric patients.
    Vorsanger G; Xiang J; Jordan D; Farrell J
    Clin Ther; 2007; 29 Suppl():2520-35. PubMed ID: 18164919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.